Page last updated: 2024-08-21

adamantane and pyrazines

adamantane has been researched along with pyrazines in 116 studies

Research

Studies (116)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (0.86)	18.2507
2000's	48 (41.38)	29.6817
2010's	66 (56.90)	24.3611
2020's	1 (0.86)	2.80

Authors

Authors	Studies
Karasawa, A; Kishibayashi, N; Suzuki, M; Tomaru, A	1
Erlich, R	1
Dasmahapatra, G; Dent, P; Grant, S; Nguyen, TK	1
Heinzl, S	1
Jago, C	1
Barnett, A	1
Drucker, DJ; Nauck, MA	1
Bailey, CJ; Flatt, PR; Green, BD	2
Anderson, KC; Barilà, D; Chauhan, D; DePinho, RA; Hideshima, T; Podar, K; Raab, MS; Raje, N; Sattler, M; Tai, YT; Tonon, G; Yasui, H; Zhang, J	1
Ahrén, B	5
Winkler, G	1
Pratley, RE; Salsali, A	1
Bloomgarden, ZT; Inzucchi, SE	1
Klein, HH; Meier, JJ; Schmidt, WE	1
Scheen, AJ	5
Amori, RE; Lau, J; Pittas, AG	1
Jennings, HR; Langley, AK; Suffoletta, TJ	1
Bandeira-Echtler, E; Bergerhoff, K; Lerch, CL; Richter, B	1
Mikhail, N	2
Deacon, CF; Holst, JJ; Krarup, T; Madsbad, S	1
Pei, Z	1
Gadsby, R	1
Doupis, J; Veves, A	1
De Meester, I; Lambeir, AM; Scharpé, S	1
Davidson, JA; Gross, JL; Parente, EB	1
Faust, M; Matthes, J	1
Fonseca, VA; John-Kalarickal, J; Wani, JH	1
Bosi, E; Lucotti, P; Monti, L; Piatti, PM; Setola, E	1
Seissler, J	1
Bandeira-Echtler, E; Bergerhoff, K; Lerch, C; Richter, B	1
Gupta, R; Pal, M; Parsa, KV; Singh, SK; Tokala, RK; Walunj, SS	1
Siddiqui, NI	1
Argyrakopoulou, G; Doupis, J	1
Nicolucci, A; Rossi, MC	1
Gallwitz, B	2
Miuchi, M; Miyagawa, J; Nanba, M	1
Gallwitz, B; Thornberry, NA	1
Curtiss, FR; Fairman, KA	1
Bode, BW	1
Barnett, AH; Palalau, AI; Piya, MK; Tahrani, AA	1
Freeman, JS	1
Schubert-Zsilavecz, M; Steinhilber, D; Zettl, H	1
Bilo, HJ; Goudswaard, AN; Houweling, ST; Kleefstra, N; Kooy, A; van Hateren, KJ; Verhoeven, S	1
Cefalu, WT	1
Guerci, B; Halter, C	1
Unger, J	1
Kuritzky, L	1
Fakhoury, WK; Lereun, C; Wright, D	1
Svec, F	1
Clar, C; Cummins, E; Marien, M; Philip, S; Richter, B; Royle, P; Waugh, N	1
Gerich, J	1
Garber, AJ	1
Campbell, RK; Cobble, ME; Reid, TS; Shomali, ME	5
Charpentier, G; Gause-Nilsson, I; Hellqvist, A; Ostgren, CJ; Scheen, AJ	1
Boudes, P; Viereck, C	1
Jellinger, PS	1
Bourdel-Marchasson, I; Dejager, S; Schweizer, A	1
Avogaro, A; de Kreutzenberg, SV; Fadini, GP; Gjini, R	1
Fan, L; Gruenberger, JB; Kantor, E; Signorovitch, JE; Swallow, E; Wu, EQ	1
Gibbs, JP; Greene, RJ; Greg Slatter, J; Tu, H	1
Jermendy, G	2
Gerrald, KR; Jonas, DE; Runge, T; Van Scoyoc, E; Wines, RC	1
Barbee, T; Correa, I; Fredrickson, J; Gibbs, JP; Gibbs, MA; Lin, SL; Smith, B	1
Alonso, JA; Carreño, C; Esteve, C; Forns, P; López, M; Maldonado, M; Miralpeix, M; Orellana, A; Ramis, I; Taboada, L; Vidal, B	1
Edwards, KL; Irons, BK; Stapleton, MR; Weis, JM	1
Dorso, C; Hamann, L; Harstad, E; Kirby, MS; Kopcho, L; Langish, R; Locke, G; Marcinkeviciene, J; Shipkova, P; Wang, A	1
Cheetham, S; Francis, J; Kirby, M; Poucher, SM; Vickers, SP; Zinker, B	1
Barbieri, M; Marfella, R; Paolisso, G; Rizzo, MR	2
Ishikawa, M; Yamada, Y	1
Colette, C; Comenducci, A; Dejager, S; Monnier, L; Vallée, D	1
Colette, C; Dejager, S; Guerci, B; Huet, D; Monnier, L; Petit, C; Quéré, S; Raccah, D; Serusclat, P; Valensi, P	1
Ando, K; Irako, T; Nishimura, R; Sakamoto, M; Tsujino, D; Utsunomiya, K	1
Abe, Y; Anabuki, J; Fukuda-Tsuru, S; Ishii, S; Yoshida, K	1
Devries, JH	1
Bakris, GL; Flynn, C	1
Barbieri, M; Boccardi, V; Esposito, A; Marfella, R; Pansini, A; Paolisso, G; Rizzo, MR	1
Blétry, O; Bouilloud, F; Crickx, E; Kahn, JE; Le Beller, C; Marroun, I; Schoindre, Y; Veyrie, C	1
Apaijai, N; Chattipakorn, N; Chattipakorn, SC; Pintana, H	2
Akahoshi, F; Ishii, S; Kadowaki, T; Kishida, H; Miyaguchi, I; Nabeno, M; Tanaka, Y	1
Cohen, D	1
Assmann, G; Brenner, C; Brunner, S; David, R; Franz, WM; Gross, L; Mueller-Hoecker, J; Nathan, P; Steinbeck, G; Theiss, HD; Vallaster, M; Vogeser, M	1
Charbonnel, B; Dejager, S; Schweizer, A	1
Batra, M; Chaudhuri, A; Dandona, P; Kuhadiya, N; Makdissi, A	1
Bae, JH; Cho, YM; Jung, HS; Kim, SY; Kim, YG; Oh, TJ; Park, KS	1
Begum, SS; Hausenloy, DJ; Mocanu, MM; Riksen, N; Theodorou, L; Whittington, HJ; Wynne, AM; Yellon, DM	1
Anz, D; Bourquin, C; Endres, S; Haubner, S; Kruger, S; Rapp, M	1
Goto, C; Mizui, T; Ohta, H; Tachi, T; Teramachi, H; Toyoshima, M; Tsuchiya, T	1
Baeschlin, DK; Beswick, M; Clark, DE; Duttaroy, A; Fenton, G; Ferreira, S; Flohr, S; Gerhartz, B; Gessier, F; Hassiepen, U; Namoto, K; Ostermann, N; Sedrani, R; Sirockin, F; Sutton, JM; Trappe, J	1
Tibaldi, JM	1
Athyros, VG; Elisaf, MS; Filippatos, TD	1
Chi, J; Gu, W; Hong, J; Ning, G; Wang, B; Wang, W; Zhang, Y	1
Marchesini, G; Melchiorri, D; Montilla, S; Pani, L; Sammarco, A; Siviero, PD; Tomino, C; Trotta, MP	1
Itoh, T; Katagiri, K; Kunitomi, N; Tominaga, M	1
Abel, AS; Averin, AD; Beletskaya, IP; Kharlamova, AD; Maloshitskaya, OA; Novakov, IA; Orlinson, BS; Roznyatovskiy, VA; Savelyev, EN	1

Reviews

61 review(s) available for adamantane and pyrazines

Article	Year
[Dipeptidylpeptidase IV inhibitors and dual action PPAR-agonists]. Medizinische Monatsschrift fur Pharmazeuten, 2006, Volume: 29, Issue:3 Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Glycine; Glycoproteins; Humans; Hypoglycemic Agents; Nitriles; Oxazoles; Peroxisome Proliferator-Activated Receptors; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2006
DPP-4 inhibitors and their potential role in the management of type 2 diabetes. International journal of clinical practice, 2006, Volume: 60, Issue:11 Topics: Adamantane; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycoproteins; Humans; Hypoglycemic Agents; Models, Animal; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2006
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet (London, England), 2006, Nov-11, Volume: 368, Issue:9548 Topics: Adamantane; Adenosine Deaminase Inhibitors; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycoproteins; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2006
Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes. Diabetes & vascular disease research, 2006, Volume: 3, Issue:3 Topics: Adamantane; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Evaluation, Preclinical; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Isoenzymes; Nitriles; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2006
Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications. Diabetes care, 2007, Volume: 30, Issue:6 Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycoproteins; Humans; Hypoglycemic Agents; Nitriles; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2007
[Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application]. Orvosi hetilap, 2007, Apr-01, Volume: 148, Issue:13 Topics: Adamantane; Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Inhibitory Polypeptide; Gastrointestinal Hormones; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Insulin Resistance; Intestinal Mucosa; Nitriles; Peptide Hormones; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2007
Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Current medical research and opinion, 2007, Volume: 23, Issue:4 Topics: Adamantane; Adenosine Deaminase Inhibitors; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucose; Glycoproteins; Homeostasis; Humans; Hypoglycemic Agents; Islets of Langerhans; Models, Biological; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2007
[New concepts in the treatment of type 2 diabetes]. Der Internist, 2007, Volume: 48, Issue:7 Topics: Adamantane; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Liraglutide; Nitriles; Peptides; Piperidines; Pyrazines; Pyrazoles; Pyrrolidines; Rimonabant; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2007
Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA, 2007, Jul-11, Volume: 298, Issue:2 Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2007
Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus. Pharmacotherapy, 2007, Volume: 27, Issue:8 Topics: Adamantane; Adenosine Deaminase Inhibitors; Administration, Oral; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Delivery Systems; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycoproteins; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2007
DPP-4 inhibitors. Best practice & research. Clinical endocrinology & metabolism, 2007, Volume: 21, Issue:4 Topics: Adamantane; Animals; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Metabolism; Metformin; Nitriles; Pioglitazone; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Substrate Specificity; Thiazolidinediones; Triazoles; Vildagliptin	2007
GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors. Current diabetes reports, 2007, Volume: 7, Issue:5 Topics: Adamantane; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Exenatide; Gastric Emptying; Glucagon-Like Peptide 1; Hypoglycemic Agents; Incretins; Islets of Langerhans; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2007
Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. The Cochrane database of systematic reviews, 2008, Apr-16, Issue:2 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Nitriles; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Vildagliptin	2008
Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. Expert opinion on investigational drugs, 2008, Volume: 17, Issue:6 Topics: Adamantane; Body Weight; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Nausea; Nitriles; Peptides; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin; Vomiting	2008
Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes. Frontiers in bioscience : a journal and virtual library, 2008, May-01, Volume: 13 Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Humans; Hypoglycemic Agents; Incretins; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2008
Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Current opinion in clinical nutrition and metabolic care, 2008, Volume: 11, Issue:4 Topics: Adamantane; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2008
Novel combination treatment of type 2 diabetes DPP-4 inhibition + metformin. Vascular health and risk management, 2008, Volume: 4, Issue:2 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Metformin; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; Vildagliptin	2008
From the bench to the bedside: dipeptidyl peptidase IV inhibitors, a new class of oral antihyperglycemic agents. Current opinion in drug discovery & development, 2008, Volume: 11, Issue:4 Topics: Adamantane; Administration, Oral; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Design; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Models, Molecular; Molecular Structure; Nitriles; Protein Conformation; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Structure-Activity Relationship; Treatment Outcome; Triazoles; Vildagliptin	2008
New treatments for type 2 diabetes--the DPP4 inhibitors. Primary care diabetes, 2007, Volume: 1, Issue:4 Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Vildagliptin	2007
DPP4 inhibitors: a new approach in diabetes treatment. Advances in therapy, 2008, Volume: 25, Issue:7 Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2008
DPP4 inhibitors for diabetes--what next? Biochemical pharmacology, 2008, Dec-15, Volume: 76, Issue:12 Topics: Adamantane; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Hypoxia; Neoplasms; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2008
Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes. Arquivos brasileiros de endocrinologia e metabologia, 2008, Volume: 52, Issue:6 Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Fasting; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Nitriles; Peptides; Postprandial Period; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2008
[Sitagliptin. DPP-4 inhibitors as a useful extension of oral diabetes therapy?]. Deutsche medizinische Wochenschrift (1946), 2008, Volume: 133, Issue:43 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Enzyme Inhibitors; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; Incretins; Insulin; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2008
Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review. Cardiology clinics, 2008, Volume: 26, Issue:4 Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2008
Incretin-based therapies in type 2 diabetes: a review of clinical results. Diabetes research and clinical practice, 2008, Dec-15, Volume: 82 Suppl 2 Topics: Adamantane; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Incretins; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2008
Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. Vascular health and risk management, 2008, Volume: 4, Issue:4 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Vildagliptin	2008
Incretin mimetics and DPP-4 inhibitors: new approach to treatment of type 2 diabetes mellitus. Mymensingh medical journal : MMJ, 2009, Volume: 18, Issue:1 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2009
DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy. Advances in therapy, 2009, Volume: 26, Issue:3 Topics: Adamantane; Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Pioglitazone; Piperidines; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Triazoles; Uracil	2009
Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes. Acta bio-medica : Atenei Parmensis, 2008, Volume: 79, Issue:3 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2008
Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential. Vascular health and risk management, 2008, Volume: 4, Issue:6 Topics: Adamantane; Blood Glucose; Body Weight; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Edema; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Lipids; Nitriles; Pioglitazone; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Thiazolidinediones; Treatment Outcome; Triazoles; Vildagliptin	2008
[The value of incretin based therapies]. Deutsche medizinische Wochenschrift (1946), 2009, Volume: 134, Issue:20 Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2009
[Incretin related agents for treatment of diabetes mellitus]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2009, Apr-10, Volume: 98, Issue:4 Topics: Adamantane; Diabetes Mellitus; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2009
Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events. Best practice & research. Clinical endocrinology & metabolism, 2009, Volume: 23, Issue:4 Topics: Adamantane; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemia; Insulin; Metformin; Nitriles; Pioglitazone; Pyrazines; Pyrrolidines; Sensitivity and Specificity; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Vildagliptin	2009
Defining the importance of daily glycemic control and implications for type 2 diabetes management. Postgraduate medicine, 2009, Volume: 121, Issue:5 Topics: Adamantane; Blood Glucose Self-Monitoring; Circadian Rhythm; Cost of Illness; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Glycated Hemoglobin; Glycemic Index; Humans; Incretins; Pyrazines; Sitagliptin Phosphate; Treatment Failure; Triazoles	2009
DPP-4 inhibitors in clinical practice. Postgraduate medicine, 2009, Volume: 121, Issue:6 Topics: Adamantane; Administration, Oral; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2009
Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus. Cleveland Clinic journal of medicine, 2009, Volume: 76 Suppl 5 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glutaminase; Homeostasis; Humans; Hypoglycemic Agents; Incretins; Intracellular Signaling Peptides and Proteins; Peptides; Pyrazines; Signal Transduction; Sitagliptin Phosphate; Triazoles; Venoms	2009
Medicinal Chemistry of Incretin Mimetics and DPP-4 Inhibitors. ChemMedChem, 2010, Feb-01, Volume: 5, Issue:2 Topics: Adamantane; Amino Acid Sequence; Chemistry, Pharmaceutical; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Insulin-Secreting Cells; Molecular Sequence Data; Nitriles; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2010
[DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia]. Pharmazie in unserer Zeit, 2010, Volume: 39, Issue:2 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2010
[New blood glucose-lowering drugs in type 2 diabetes: a review of the literature]. Nederlands tijdschrift voor geneeskunde, 2010, Volume: 154 Topics: Adamantane; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Vildagliptin	2010
The physiologic role of incretin hormones: clinical applications. The Journal of the American Osteopathic Association, 2010, Volume: 110, Issue:3 Suppl 2 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Incretins; Piperidines; Pyrazines; Sitagliptin Phosphate; Triazoles; Uracil	2010
Managing type 2 diabetes in the primary care setting: beyond glucocentricity. The American journal of the medical sciences, 2010, Volume: 340, Issue:2 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Hypoglycemic Agents; Liraglutide; Nitriles; Obesity; Patient Compliance; Peptides; Piperidines; Precision Medicine; Primary Health Care; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin	2010
Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:8 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Half-Life; Humans; Hypoglycemic Agents; Male; Nitriles; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Vildagliptin	2010
A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology, 2010, Volume: 86, Issue:1 Topics: Adamantane; Adult; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin; Weight Loss	2010
Incretin physiology and its role in type 2 diabetes mellitus. The Journal of the American Osteopathic Association, 2010, Volume: 110, Issue:7 Suppl 7 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms	2010
Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. Health technology assessment (Winchester, England), 2010, Volume: 14, Issue:36 Topics: Adamantane; Body Weight; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Nitriles; Peptides; Pyrazines; Pyrrolidines; Quality of Life; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; State Medicine; Thiazolidinediones; Triazoles; United Kingdom; Venoms; Vildagliptin	2010
Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clinical pharmacokinetics, 2010, Volume: 49, Issue:9 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin	2010
DPP-4 inhibitors: what may be the clinical differentiators? Diabetes research and clinical practice, 2010, Volume: 90, Issue:2 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Energy Intake; Gastric Emptying; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Intestinal Mucosa; Linagliptin; Neurons; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin	2010
Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting. The American journal of managed care, 2010, Volume: 16, Issue:7 Suppl Topics: Adamantane; Algorithms; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Evidence-Based Medicine; Exenatide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Secretion; Liraglutide; Managed Care Programs; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms	2010
Focus on incretin-based therapies: targeting the core defects of type 2 diabetes. Postgraduate medicine, 2011, Volume: 123, Issue:1 Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Liraglutide; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms	2011
Incretin therapies in the management of elderly patients with type 2 diabetes mellitus. Hospital practice (1995), 2011, Volume: 39, Issue:1 Topics: Adamantane; Age Factors; Aged; Aging; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Male; Middle Aged; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Vildagliptin	2011
[Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs]. Orvosi hetilap, 2011, Sep-11, Volume: 152, Issue:37 Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Metformin; Nitriles; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Tablets; Treatment Outcome; Triazoles; Vildagliptin	2011
[Incretin-based therapy for treating patients with type 2 diabetes]. Orvosi hetilap, 2011, Nov-27, Volume: 152, Issue:48 Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin	2011
Saxagliptin and sitagliptin in adult patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:6 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2012
Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results. Journal of clinical pharmacology, 2012, Volume: 52, Issue:10 Topics: Adamantane; Biomarkers; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Models, Biological; Nitriles; Piperidines; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin	2012
DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes & metabolism, 2012, Volume: 38, Issue:2 Topics: Adamantane; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin; Weight Gain	2012
An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors. Current diabetes reviews, 2012, Volume: 8, Issue:3 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Glucagon-Like Peptide 1; Humans; Linagliptin; Male; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin	2012
Noninsulin glucose-lowering agents for the treatment of patients on dialysis. Nature reviews. Nephrology, 2013, Volume: 9, Issue:3 Topics: Adamantane; Biguanides; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Glucagon-Like Peptides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Meglumine; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Dialysis; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Uracil; Vildagliptin	2013
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence? Hospital practice (1995), 2013, Volume: 41, Issue:2 Topics: Adamantane; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin	2013
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes. Postgraduate medicine, 2013, Volume: 125, Issue:3 Topics: Adamantane; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular System; Coronary Artery Disease; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Lipids; Nitriles; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Vildagliptin	2013
Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes. Advances in therapy, 2014, Volume: 31, Issue:3 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Linagliptin; Liraglutide; Peptides; Piperidines; Purines; Pyrazines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Weight Loss	2014
The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected]. Expert opinion on drug metabolism & toxicology, 2014, Volume: 10, Issue:6 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Piperidones; Purines; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Thiazolidines; Triazoles; Uracil; Vildagliptin	2014

Trials

9 trial(s) available for adamantane and pyrazines

Article	Year
Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes/metabolism research and reviews, 2010, Volume: 26, Issue:7 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles	2010
The metabolic syndrome influences the response to incretin-based therapies. Acta diabetologica, 2011, Volume: 48, Issue:3 Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Male; Metabolic Syndrome; Middle Aged; Nitriles; Peptides; Prognosis; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Vildagliptin	2011
Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results. Journal of clinical pharmacology, 2012, Volume: 52, Issue:10 Topics: Adamantane; Biomarkers; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Models, Biological; Nitriles; Piperidines; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin	2012
Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes care, 2012, Volume: 35, Issue:10 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Inflammation; Interleukin-18; Interleukin-6; Male; Metformin; Middle Aged; Nitriles; Oxidative Stress; Postprandial Period; Prospective Studies; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2012
Add-on therapies to metformin in type 2 diabetes: what modulates the respective decrements in postprandial and basal glucose? Diabetes technology & therapeutics, 2012, Volume: 14, Issue:10 Topics: Adamantane; Adult; Aged; Analysis of Variance; Area Under Curve; Basal Metabolism; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Pyrazines; Pyrrolidines; Rosiglitazone; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Vildagliptin	2012
Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study. Diabetes & metabolism, 2012, Volume: 38, Issue:4 Topics: Adamantane; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; France; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Nitriles; Pilot Projects; Prospective Studies; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Vildagliptin; Young Adult	2012
Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study). Cardiovascular diabetology, 2012, Aug-06, Volume: 11 Topics: Adamantane; Adult; Aged; Biomarkers; Blood Glucose; C-Peptide; Cross-Over Studies; Deoxyglucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Female; Glycated Hemoglobin; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Japan; Male; Middle Aged; Monitoring, Ambulatory; Natriuretic Peptide, Brain; Nitriles; Pilot Projects; Plasminogen Activator Inhibitor 1; Postprandial Period; Predictive Value of Tests; Pyrazines; Pyrrolidines; Serum Albumin; Sitagliptin Phosphate; Time Factors; Treatment Outcome; Triazoles; Vildagliptin	2012
Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis, 2013, Volume: 227, Issue:2 Topics: Adamantane; Atherosclerosis; Blood Glucose; Carotid Arteries; Carotid Artery Diseases; Carotid Intima-Media Thickness; Cytokines; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Inflammation; Nitriles; Oxidative Stress; Prospective Studies; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Tyrosine; Vildagliptin	2013
Different effects of two dipeptidyl peptidase-4 inhibitors and glimepiride on β-cell function in a newly designed two-step hyperglycemic clamp. Journal of diabetes, 2015, Volume: 7, Issue:2 Topics: Adamantane; Adult; Blood Glucose; Cross-Over Studies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Follow-Up Studies; Glucose Clamp Technique; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin-Secreting Cells; Male; Prognosis; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Triazoles	2015

Other Studies

47 other study(ies) available for adamantane and pyrazines

Article	Year
Effects of the adenosine A1-receptor antagonist on defecation, small intestinal propulsion and gastric emptying in rats. Japanese journal of pharmacology, 1995, Volume: 68, Issue:1 Topics: Adamantane; Animals; Bisacodyl; Defecation; Gastric Emptying; Gastrointestinal Motility; Imidazoles; Intestine, Small; Male; Purinergic P1 Receptor Antagonists; Pyrazines; Quinazolines; Rats; Rats, Sprague-Dawley; Triazoles; Xanthines	1995
American Diabetes Association - 65th Scientific Sessions. DDP-IV inhibitors. IDrugs : the investigational drugs journal, 2005, Volume: 8, Issue:8 Topics: Adamantane; Animals; Dipeptidyl Peptidase 4; Glucagon; Glucagon-Like Peptide 1; Humans; Islets of Langerhans; Nitriles; Peptide Fragments; Protease Inhibitors; Protein Precursors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin; Xanthines	2005
Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr/Abl. Leukemia research, 2006, Volume: 30, Issue:10 Topics: Adamantane; Antineoplastic Agents; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Cell Line, Tumor; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Hydroquinones; Imatinib Mesylate; Kinetics; Mutation; Oxidative Stress; Piperazines; Point Mutation; Pyrazines; Pyrimidines; Reactive Oxygen Species	2006
American Diabetes Association--66th scientific sessions. 9-13 June 2006, Washington, DC, USA. IDrugs : the investigational drugs journal, 2006, Volume: 9, Issue:8 Topics: Adamantane; Clinical Trials as Topic; Glucagon-Like Peptide 1; Humans; Liraglutide; Nitriles; Peripheral Vascular Diseases; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2006
Oral agents for type 2 diabetes reduce HbA1c, are weight neutral. Geriatrics, 2006, Volume: 61, Issue:9 Topics: Adamantane; Administration, Oral; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2006
Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma. Cancer research, 2007, Feb-15, Volume: 67, Issue:4 Topics: Adamantane; Apoptosis; Benzamides; Boronic Acids; Bortezomib; Caspase Inhibitors; Caspases; Cell Growth Processes; Dexamethasone; Humans; Hydroquinones; Imatinib Mesylate; Leukemia, Erythroblastic, Acute; Melphalan; Multiple Myeloma; Piperazines; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-jun; Pyrazines; Pyrimidines; Transfection; Up-Regulation	2007
New treatments for diabetes. The New England journal of medicine, 2007, May-24, Volume: 356, Issue:21 Topics: Adamantane; Adenosine Deaminase Inhibitors; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glipizide; Glycated Hemoglobin; Glycoproteins; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Vildagliptin	2007
[Glucagon-like peptide-1 (GLP-1), new target for the treatment of type 2 diabetes]. Revue medicale de Liege, 2007, Volume: 62, Issue:4 Topics: Adamantane; Animals; Appetite; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2007
Three new drugs for type 2 diabetes. Drug and therapeutics bulletin, 2008, Volume: 46, Issue:7 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Humans; Hypoglycemic Agents; Incretins; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Venoms; Vildagliptin	2008
[Future therapeutic options and their indications: transplantation and the possibilities of regenerative therapy for diabetes type 1]. MMW Fortschritte der Medizin, 2008, Oct-30, Volume: 150, Issue:44 Topics: Adamantane; Animals; Diabetes Mellitus, Type 1; Exenatide; Humans; Insulin-Secreting Cells; Islets of Langerhans; Islets of Langerhans Transplantation; Mice; Nitriles; Peptides; Pyrazines; Pyrrolidines; Regeneration; Sitagliptin Phosphate; Stem Cell Transplantation; Transplantation, Heterologous; Triazoles; Venoms; Vildagliptin	2008
Emerging drug candidates of dipeptidyl peptidase IV (DPP IV) inhibitor class for the treatment of Type 2 Diabetes. Current drug targets, 2009, Volume: 10, Issue:1 Topics: Adamantane; Animals; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drugs, Investigational; Humans; Hypoglycemic Agents; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Substrate Specificity; Treatment Outcome; Triazoles; Vildagliptin	2009
Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best practice & research. Clinical endocrinology & metabolism, 2009, Volume: 23, Issue:4 Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2009
Call for comparative effectiveness research: lowering A1c with sitagliptin, saxagliptin, or cinnamon. Journal of managed care pharmacy : JMCP, 2009, Volume: 15, Issue:8 Topics: Adamantane; Cinnamomum zeylanicum; Comparative Effectiveness Research; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles	2009
[New hypoglycemic agents in type 2 diabetes]. La Revue du praticien, 2010, Apr-20, Volume: 60, Issue:4 Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Liraglutide; Nitriles; Peptides; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2010
Choosing among the incretin agents and why it matters. The Journal of family practice, 2010, Volume: 59, Issue:5 Suppl Topics: Adamantane; Blood Pressure; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Lipids; Liraglutide; Male; Middle Aged; Peptides; Pyrazines; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss	2010
Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies. The Journal of family practice, 2010, Volume: 59, Issue:9 Suppl 1 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms	2010
Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies. The Journal of family practice, 2010, Volume: 59, Issue:9 Suppl 1 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Risk; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss	2010
Distinguishing among incretin-based therapies. Patient education and self-management. The Journal of family practice, 2010, Volume: 59, Issue:9 Suppl 1 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Patient Education as Topic; Peptides; Pyrazines; Receptors, Glucagon; Self Care; Sitagliptin Phosphate; Triazoles; Venoms	2010
Distinguishing among incretin-based therapies. Introduction. The Journal of family practice, 2010, Volume: 59, Issue:9 Suppl 1 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Exenatide; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Insulin-Secreting Cells; Liraglutide; Metformin; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms	2010
Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies. The Journal of family practice, 2010, Volume: 59, Issue:9 Suppl 1 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Time Factors; Triazoles; Venoms	2010
An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development. Contemporary clinical trials, 2011, Volume: 32, Issue:3 Topics: Adamantane; Allylamine; Cardiovascular Diseases; Colesevelam Hydrochloride; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Investigational New Drug Application; Liraglutide; Nitriles; Peptides; Piperidines; Practice Guidelines as Topic; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Time Factors; Triazoles; United States; United States Food and Drug Administration; Uracil; Venoms; Vildagliptin	2011
Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials. Clinical drug investigation, 2011, Volume: 31, Issue:9 Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Female; Glycated Hemoglobin; Humans; Japan; Male; Middle Aged; Nitriles; Pyrazines; Pyrrolidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Triazoles; Vildagliptin	2011
Target-mediated metabolism and target-mediated drug disposition of the DPPIV inhibitor AMG 222. Xenobiotica; the fate of foreign compounds in biological systems, 2011, Volume: 41, Issue:11 Topics: Adamantane; Amides; Blood Proteins; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Dibenzocycloheptenes; Dipeptidyl-Peptidase IV Inhibitors; Drug Delivery Systems; Humans; Inhibitory Concentration 50; Kinetics; Nitriles; Protein Binding; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Tetrazoles; Time Factors; Triazoles; Ultracentrifugation; Vildagliptin	2011
Pyrazine-based Syk kinase inhibitors. Bioorganic & medicinal chemistry letters, 2012, Apr-15, Volume: 22, Issue:8 Topics: Adamantane; Cell Line, Tumor; Crystallography, X-Ray; Enzyme Activation; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Molecular Structure; Protein-Tyrosine Kinases; Pyrazines; Syk Kinase	2012
Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor. BMC pharmacology, 2012, Apr-04, Volume: 12 Topics: Adamantane; Algorithms; Animals; Artifacts; Cloning, Molecular; Dipeptidases; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Indicators and Reagents; Kinetics; Macaca fascicularis; Nitriles; Protein Binding; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Species Specificity; Triazoles; Vildagliptin	2012
Effects of saxagliptin and sitagliptin on glycaemic control and pancreatic β-cell mass in a streptozotocin-induced mouse model of type 2 diabetes. Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:10 Topics: Adamantane; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Dipeptides; Drinking; Eating; Glucose Tolerance Test; Glycated Hemoglobin; Hypoglycemic Agents; Immunohistochemistry; Insulin-Secreting Cells; Male; Mice; Mice, Inbred C57BL; Pyrazines; Sitagliptin Phosphate; Triazoles	2012
[Therapeutic use and adverse events of incretin-related drugs]. Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70 Suppl 3 Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin	2012
A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations. European journal of pharmacology, 2012, Dec-05, Volume: 696, Issue:1-3 Topics: Adamantane; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Hyperglycemia; Hypertriglyceridemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Nitriles; Pyrazines; Pyrazoles; Pyrrolidines; Rats; Rats, Wistar; Rats, Zucker; Sitagliptin Phosphate; Thiazolidines; Triazoles; Vildagliptin	2012
Comment on: Rizzo et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082. Diabetes care, 2013, Volume: 36, Issue:1 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Nitriles; Pyrazines; Pyrrolidines; Triazoles	2013
Response to Comment on: Rizzo et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082. Diabetes care, 2013, Volume: 36, Issue:1 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Nitriles; Pyrazines; Pyrrolidines; Triazoles	2013
DPP4 inhibitor-induced polyarthritis: a report of three cases. Rheumatology international, 2014, Volume: 34, Issue:2 Topics: Adamantane; Arthritis; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitriles; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Vildagliptin	2014
Effects of vildagliptin versus sitagliptin, on cardiac function, heart rate variability and mitochondrial function in obese insulin-resistant rats. British journal of pharmacology, 2013, Volume: 169, Issue:5 Topics: Adamantane; Animals; Blood Glucose; Blood Pressure; Body Weight; Cardiotonic Agents; Cholesterol; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Heart; Heart Rate; Insulin; Insulin Resistance; Male; Malondialdehyde; Membrane Potential, Mitochondrial; Mitochondria, Heart; Nitriles; Obesity; Oxidative Stress; Pyrazines; Pyrrolidines; Rats, Wistar; Reactive Oxygen Species; Sitagliptin Phosphate; Triazoles; Vildagliptin	2013
A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site. Biochemical and biophysical research communications, 2013, May-03, Volume: 434, Issue:2 Topics: Adamantane; Catalytic Domain; Crystallography, X-Ray; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Humans; Multiprotein Complexes; Nitriles; Oligopeptides; Piperidines; Protein Binding; Protein Interaction Mapping; Pyrazines; Pyrazoles; Pyrrolidines; Serine; Sitagliptin Phosphate; Structure-Activity Relationship; Thiazolidines; Triazoles; Uracil; Vildagliptin; X-Ray Diffraction	2013
DPP-4 inhibitors improve cognition and brain mitochondrial function of insulin-resistant rats. The Journal of endocrinology, 2013, Volume: 218, Issue:1 Topics: Adamantane; Animals; Behavior, Animal; Brain; Cognition Disorders; Diabetes Mellitus, Type 2; Diet, High-Fat; Dipeptidyl-Peptidase IV Inhibitors; Hippocampus; Insulin Resistance; Male; Maze Learning; Memory; Memory Disorders; Mitochondria; Nitriles; Obesity; Oxidative Stress; Pyrazines; Pyrrolidines; Rats; Rats, Wistar; Sitagliptin Phosphate; Triazoles; Vildagliptin	2013
Reports of pancreatitis are 20-30 times more likely with GLP-1 drugs, analysis finds. BMJ (Clinical research ed.), 2013, Apr-23, Volume: 346 Topics: Adamantane; Diabetes Mellitus; Dipeptides; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Linagliptin; Pancreatitis; Purines; Pyrazines; Quinazolines; Sitagliptin Phosphate; Triazoles; United States	2013
Antidiabetic gliptins in combination with G-CSF enhances myocardial function and survival after acute myocardial infarction. International journal of cardiology, 2013, Oct-09, Volume: 168, Issue:4 Topics: Adamantane; Animals; Cell Survival; Drug Therapy, Combination; Granulocyte Colony-Stimulating Factor; Heart; Hypoglycemic Agents; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2013
Comment on: Rizzo et al. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 2012;35:2076-2082. Diabetes care, 2013, Volume: 36, Issue:6 Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Male; Nitriles; Pyrazines; Pyrrolidines; Triazoles	2013
Clinical characteristics of the responders to dipeptidyl peptidase-4 inhibitors in Korean subjects with type 2 diabetes. Journal of Korean medical science, 2013, Volume: 28, Issue:6 Topics: Adamantane; Blood Glucose; Body Mass Index; C-Peptide; Creatinine; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Humans; Insulin Resistance; Male; Middle Aged; Multivariate Analysis; Nitriles; Pyrazines; Pyrrolidines; Retrospective Studies; Sitagliptin Phosphate; Triazoles; Vildagliptin	2013
Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner. Cardiovascular diabetology, 2013, Oct-22, Volume: 12 Topics: Adamantane; Animals; Cyclic AMP-Dependent Protein Kinases; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glucose; Heart; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Nitriles; Pyrazines; Pyrrolidines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Receptors, Glucagon; Severity of Illness Index; Signal Transduction; Sitagliptin Phosphate; Triazoles; Vildagliptin	2013
The dipeptidylpeptidase-IV inhibitors sitagliptin, vildagliptin and saxagliptin do not impair innate and adaptive immune responses. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:6 Topics: Adamantane; Adaptive Immunity; Animals; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Immunity, Innate; Mice; Nitriles; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; T-Lymphocytes; Triazoles; Vildagliptin	2014
Pharmacoeconomic analysis of DPP-4 inhibitors. Die Pharmazie, 2013, Volume: 68, Issue:11 Topics: Adamantane; Clinical Trials as Topic; Cohort Studies; Cost-Benefit Analysis; Costs and Cost Analysis; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Nitriles; Piperidines; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin	2013
Discovery of C-(1-aryl-cyclohexyl)-methylamines as selective, orally available inhibitors of dipeptidyl peptidase IV. Bioorganic & medicinal chemistry letters, 2014, Feb-01, Volume: 24, Issue:3 Topics: Adamantane; Administration, Oral; Animals; Caco-2 Cells; Crystallography, X-Ray; Cyclization; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Discovery; Enzyme Activation; Humans; Inhibitory Concentration 50; Methylamines; Molecular Structure; Nitriles; Pyrazines; Pyrrolidines; Rats; Sitagliptin Phosphate; Triazoles; Vildagliptin	2014
Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: data from the Italian AIFA Anti-diabetics Monitoring Registry. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2014, Volume: 24, Issue:12 Topics: Adamantane; Aged; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Drug Utilization; Drug-Related Side Effects and Adverse Reactions; Exenatide; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Italy; Male; Metformin; Middle Aged; Monitoring, Physiologic; Nitriles; Peptides; Pyrazines; Pyrrolidines; Registries; Sex Factors; Sitagliptin Phosphate; Triazoles; Venoms; Vildagliptin	2014
[Dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin. Cardiovascular safety in type 2 diabetics]. MMW Fortschritte der Medizin, 2014, Jul-24, Volume: 156, Issue:13 Topics: Adamantane; Adult; Aged; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Middle Aged; Nitriles; Pyrazines; Pyrrolidines; Risk Factors; Sitagliptin Phosphate; Triazoles; Vildagliptin	2014
Adamantane-based oxacyclophanes containing pyrazines: synthesis, crystal structure, and self-assembly behavior. Organic letters, 2015, Feb-20, Volume: 17, Issue:4 Topics: Adamantane; Crystallography, X-Ray; Ethers, Cyclic; Molecular Conformation; Pyrazines	2015
Gliptins: bullous pemphigoid. Prescrire international, 2015, Volume: 24, Issue:158 Topics: Adamantane; Aged; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Male; Nitriles; Pemphigoid, Bullous; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Triazoles; Vildagliptin	2015
Mono- and Diamination of 4,6-Dichloropyrimidine, 2,6-Dichloropyrazine and 1,3-Dichloroisoquinoline with Adamantane-Containing Amines. Molecules (Basel, Switzerland), 2021, Mar-29, Volume: 26, Issue:7 Topics: Adamantane; Amination; Amines; Catalysis; Molecular Structure; Pyrazines	2021